Lung cancer has the highest incidence and mortality rates among malignant tumors both in China and worldwide, with approximately 85% of cases being non-small cell lung cancer (NSCLC). In the diagnosis and treatment of lung cancer, conventional imaging and tissue biopsy are often limited by insufficient sensitivity or invasive risks, making it difficult to meet the demands of future precision medicine. In recent years, artificial intelligence (AI)-based radiomics and autoantibody-based liquid biopsy have developed rapidly and have become major research focuses. AI radiomics significantly improves the accuracy of traditional imaging diagnosis by autonomously learning from large-scale imaging databases. Autoantibody liquid biopsy, on the other hand, utilizes tumor-associated autoantigens and antibodies as biomarkers, offering the advantages of being non-invasive, precise, efficient, and capable of reflecting spatiotemporal tumor heterogeneity, thereby demonstrating great potential in NSCLC diagnosis and treatment. This review summarizes recent research advances in autoantibody liquid biopsy and AI radiomics for the management of lung cancer.
Stroke has the characteristics of high incidence rate, high mortality rate and high disability rate. Most patients may have some motor dysfunction after stroke, which greatly affects the normal life of patients. As a common sequela after stroke, foot drop seriously affects the walking gait of patients, limits the activities of patients, and reduces their quality of life. In recent years, repetitive peripheral magnetic stimulation (rPMS) has been used more and more in the rehabilitation of various diseases. Because rPMS is noninvasive, affordable and effective, it is accepted by many patients. This article reviews the research progress of rPMS for foot drop after stroke.
Lung cancer is the malignant tumor with the highest incidence and mortality in China and even worldwide. Non-small cell lung cancer (NSCLC) constitutes the vast majority of cases. The current innovation in lung cancer diagnosis and treatment systems is progressively transitioning from traditional pathological classification to molecular characteristic-guided precision medicine. However, the conventional gold standard for molecular detection, tissue biopsy, faces limitations including invasive procedures and non-repeatable sample acquisition. The breakthrough in liquid biopsy technology has provided new clinical pathways, particularly through circulating tumor DNA (ctDNA) detection for molecular residual disease (MRD) monitoring, which has emerged as a research hotspot in the liquid biopsy field. Through continuous optimization, this approach has achieved breakthroughs in high sensitivity and specificity. Its non-invasive nature eliminates the risks associated with tissue puncture, demonstrating significant potential in various clinical applications including early and advanced NSCLC diagnosis, treatment response monitoring, drug resistance evaluation, and prognosis prediction.